Shares of Mirna Therapeutics Inc. (NASDAQ:MIRN) have been given an average rating of “Hold” by the six ratings firms that are currently covering the firm. Five research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $2.05.

A number of research analysts have recently commented on MIRN shares. Oppenheimer Holdings Inc. increased their price objective on Mirna Therapeutics from $7.00 to $13.00 and gave the company an “outperform” rating in a report on Tuesday, August 16th. Citigroup Inc. dropped their price objective on Mirna Therapeutics from $4.50 to $2.00 and set a “neutral” rating on the stock in a report on Thursday, September 22nd. Zacks Investment Research upgraded Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a report on Wednesday, September 7th. Leerink Swann cut Mirna Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $10.00 to $4.00 in a research report on Monday, August 15th. Finally, HC Wainwright initiated coverage on Mirna Therapeutics in a research report on Monday, September 12th. They issued a “buy” rating and a $6.00 target price for the company.

Shares of Mirna Therapeutics (NASDAQ:MIRN) traded down 4.06% on Monday, reaching $1.66. The company had a trading volume of 4,144 shares. The firm’s market capitalization is $34.59 million. Mirna Therapeutics has a 52 week low of $1.66 and a 52 week high of $11.01. The company’s 50-day moving average price is $2.20 and its 200 day moving average price is $3.78.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Mirna Therapeutics Company Profile

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

5 Day Chart for NASDAQ:MIRN

Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with's FREE daily email newsletter.